A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment

Restricted access

Object

The purpose of this study was to validate a new prognostic index for patients with brain metastases. This index, the Graded Prognostic Assessment (GPA), is based on an analysis of 1960 patients whose data were extracted from the Radiation Therapy Oncology Group (RTOG) database. The GPA is based on 4 criteria: age, Karnofsky Performance Scale score, number of brain metastases, and the presence/absence of extracranial metastases. Each of the 4 criteria is given a score of 0, 0.5, or 1.0, so the patient with best prognosis would have a GPA score of 4.0.

Methods

Between April 2005 and December 2006, 140 eligible patients with brain metastases were treated at the Gamma Knife Center at the University of Minnesota. The GPA score was calculated for each patient, and the score was then correlated with survival. Survival duration was calculated from the date treatment began for the brain metastases. Eligibility criteria included patients treated with whole-brain radiation therapy, stereotactic radiosurgery, or both.

Results

The median survival time in months observed in the RTOG and Minnesota data by GPA score was as follows: GPA 3.5–4.0, 11.0 and 21.7; GPA 3.0, 8.9 and 17.5; GPA 1.5–2.5, 3.8 and 5.9; and GPA 0–1.0, 2.6 and 3.0, respectively.

Conclusions

The University of Minnesota data correlate well with the RTOG data and validate the use of the GPA as an effective prognostic index for patients with brain metastases. Clearly, not all patients with brain metastases have the same prognosis, and treatment decisions should be individualized accordingly. The GPA score does appear to be as prognostic as the RPA and is less subjective (because the RPA requires assessment of whether the primary disease is controlled), more quantitative, and easier to use and remember. A multiinstitutional validation study of the GPA is ongoing.

Abbreviations used in this paper: GPA = Graded Prognostic Assessment; MST = median survival time; RPA = recursive partitioning analysis; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy.

Article Information

Address correspondence to: Paul Sperduto, M.D, M.P.P., Department of Radiation Oncology, Gamma Knife Center, 420 Delaware Street, MMC 494, Minneapolis, Minnesota 55113. email: psperduto@mropa.com.

© AANS, except where prohibited by US copyright law.

Headings

References

1

Andrews DWScott CBSperduto PWFlanders AEGaspar LESchell MC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:166516722004

2

Gaspar LScott CRotman MAsbell SPhillips TWasserman T: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:7457511997

3

Posner JB: Management of brain metastases. Rev Neurol 148:4774871992

4

Sperduto PWBerkey BGaspar LEMehta MCurran W: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:5105142008

5

Wen PYLoeffler JS: Management of brain metastases. Oncology 13:9419541999

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 22 22 9
Full Text Views 66 66 20
PDF Downloads 51 51 6
EPUB Downloads 0 0 0

PubMed

Google Scholar